China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)

SHE:300294 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,847	1,734	2,651	2,761	2,645	2,510
Other Revenue	0.22	0.79	0.85	-2.22	5.21	3.36
Revenue	1,847	1,735	2,652	2,759	2,651	2,513
Revenue Growth (YoY)	-7.97%	-34.58%	-3.87%	4.08%	5.47%	-13.61%
Cost of Revenue	794	615.97	1,259	1,255	1,187	1,055
Gross Profit	1,053	1,119	1,393	1,504	1,463	1,458
Selling, General & Admin	639.14	603.65	774.85	923.64	969.52	1,039
Research & Development	59.75	66.89	67.7	49.58	59.29	89.05
Other Operating Expenses	2.99	17.47	18.98	20.83	19.99	8.93
Operating Expenses	714.16	696.81	863.9	996.86	1,049	1,128
Operating Income	338.78	422.12	529.38	507.16	414.49	330.18
Interest Expense	-1.01	-0.66	-0.46	-0.62	-10.53	-21.45
Interest & Investment Income	28.23	42.49	45.31	64.93	63.9	22.96
Currency Exchange Gain (Loss)	-2.77	-2.77	-	-	-	-
Other Non Operating Income (Expenses)	2.79	0.87	-0.43	4.02	-8.3	-3.07
EBT Excluding Unusual Items	366.02	462.05	573.81	575.49	459.57	328.63
Impairment of Goodwill	-72.61	-72.61	-298.41	-	-	-
Gain (Loss) on Sale of Investments	63.5	65.58	85.74	-	10.71	-
Gain (Loss) on Sale of Assets	4.79	-0.61	1.3	0.07	-0.87	-1.58
Asset Writedown	-11.41	-11.18	-28.31	-51.03	-36.37	-0.27
Other Unusual Items	23.07	34.49	19.59	7.47	10.08	1.36
Pretax Income	373.35	477.71	353.71	532	443.12	328.13
Income Tax Expense	67.11	81.19	105.56	86.51	84.84	52.87
Earnings From Continuing Operations	306.24	396.53	248.15	445.49	358.28	275.26
Minority Interest in Earnings	0.13	0.46	-10.68	-13.29	-13.75	-15.2
Net Income	306.36	396.99	237.47	432.2	344.53	260.06
Net Income to Common	306.36	396.99	237.47	432.2	344.53	260.06
Net Income Growth	34.65%	67.18%	-45.06%	25.45%	32.48%	-38.97%
Shares Outstanding (Basic)	502	503	505	503	436	426
Shares Outstanding (Diluted)	502	503	505	503	436	426
Shares Change (YoY)	-0.63%	-0.54%	0.53%	15.24%	2.30%	0.04%
EPS (Basic)	0.61	0.79	0.47	0.86	0.79	0.61
EPS (Diluted)	0.61	0.79	0.47	0.86	0.79	0.61
EPS Growth	35.51%	68.08%	-45.35%	8.86%	29.51%	-39.00%
Free Cash Flow	-332.32	101.99	554.23	458.03	1,277	576.07
Free Cash Flow Per Share	-0.66	0.20	1.10	0.91	2.93	1.35
Dividend Per Share	0.160	0.320	0.300	0.200	0.150	0.065
Dividend Growth	-65.22%	6.67%	50.00%	33.33%	130.77%	-56.67%
Gross Margin	57.01%	64.50%	52.54%	54.52%	55.21%	58.01%
Operating Margin	18.34%	24.33%	19.96%	18.38%	15.64%	13.14%
Profit Margin	16.59%	22.88%	8.95%	15.67%	13.00%	10.35%
Free Cash Flow Margin	-17.99%	5.88%	20.90%	16.60%	48.19%	22.92%
EBITDA	469.34	519.84	624.38	600.38	510.65	411.52
EBITDA Margin	25.41%	29.96%	23.54%	21.76%	19.27%	16.38%
D&A For EBITDA	130.55	97.71	94.99	93.22	96.16	81.34
EBIT	338.78	422.12	529.38	507.16	414.49	330.18
EBIT Margin	18.34%	24.33%	19.96%	18.38%	15.64%	13.14%
Effective Tax Rate	17.98%	16.99%	29.84%	16.26%	19.15%	16.11%
Revenue as Reported	1,847	1,735	2,652	2,759	2,651	-
Advertising Expenses	-	3.26	2.73	1.82	2.5	1.77

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.